The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

The'magic bullet'concept of specifically targeting cancer cells at the same time as sparing
normal tissues is now proven, as several monoclonal antibodies and targeted small …

Introduction: We evaluated the ability of histopathologic response criteria to predict overall
survival (OS) and disease-free survival (DFS) in patients with surgically resected non-small …

The cell cycle represents a series of tightly integrated events that allow the cell to grow and
proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Background Somatic mutations of the k-RAS oncogene have been assessed as a
mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine …

The basal molecular subtype of breast cancer (BC) is defined by the mRNA expression
pattern of an intrinsic∼ 500‐gene set. It is the most homogeneous subtype in transcriptional …

While cisplatin and carboplatin are active versus most common cancers, epithelial
malignancies are incurable when metastatic. Even if an initial response occurs, acquired …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways by over-
expression or constitutive activation can promote tumor processes including angiogenesis …